Notícias e Atividades da ProMIS Neurosciences
Presença
ProMIS Neurosciences é uma empresa listada sob o símbolo PMN (US).
Executivos
Veja o organograma con seus 10 executivos principais
Biografias mais buscadas da ProMIS Neurosciences
- Neil Warma, President and Chief Executive Officer
- Eugene Williams, Chairman of the Board
- William Wyman, Director
Recentes movimentos de executivos em ProMIS Neurosciences
- Gavin Malenfant, Chief Operating Officer, deixou a Companhia (Notícia publicada em 20 de fevereiro de 2025).
Criar um alerta
para seguir os movimentos de executivos da ProMIS Neurosciences.
Biotecnologia
ProMIS Neurosciences possui 2.339 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Biogen (Estados Unidos).
Popular M&A news in Biotecnologia
- Jade Biosciences and Aerovate Therapeutics have announced they will merge (publicado em 30 de abril de 2025)..
- Deepull acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 29 de abril de 2025).
- Biolinq acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 23 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de ProMIS Neurosciences
- ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
- ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
- ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
- ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
- ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
- ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
- ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
- ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
- ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
- View more press releases Close
Redes sociais sobre ProMIS Neurosciences
- ProMIS Neurosciences na Wikipedia, Google News e Yahoo Finance
- ProMIS Neurosciences na LinkedIn, Twitter e YouTube
